BMI1 is a core protein of the polycomb repressive complex 1 (PRC1) that is overexpressed in several 15 cancer types, making it a promising target for cancer therapies. However, the underlying mechanisms 16 and interactions associated with BMI1-induced tumorigenesis are often context-dependent and 17 complex. Here, we performed a drug resistance screen on mutagenized human haploid HAP1 cells 18 treated with the BMI1 inhibitor PTC-318 to find new genetic and mechanistic features associated with 19 BMI1-dependent cancer cell proliferation. Our screen identified NUMA1-mutations as the most 20 significant inducer of PTC-318 cell death resistance. Independent validations on NUMA1-proficient 21 HAP1 and non-small cell lung cancer cell lines exposed to BMI1 inhibition by PTC-318 or BMI1 22 knockdown resulted in cell death following mitotic arrest. Interestingly, cells with CRISPR-Cas9 23 derived NUMA1 knockout also showed a mitotic arrest phenotype following BMI1 inhibition but, 24 contrary to cells with wildtype NUMA1, these cells were resistant to BMI1-dependent cell death. The
Introduction 28
The chromatin-modifying Polycomb-group proteins are critical epigenetic transcriptional repressors 29 controlling cell fate decisions, such as self-renewal and differentiation of stem cells, as well as 30 tumorigenesis, primarily through the repression of downstream genes (1-3). B lymphoma Mo-MLV 31 insertion region 1 homolog (BMI1), an essential protein of the polycomb repressive complex 1 (PRC1),
32
was first identified as an oncogene, inducing lymphomas in mice by co-operating with c-MYC (4, 5) .
33
The protein is often expressed in stem cells, and several reports have implicated its overexpression in 34 cancer stem cell maintenance and the progression of different types of cancers (6) (7) (8) . By contrast,
35
regulation of BMI1 using inhibitors or short hairpin RNAs results in cellular senescence or apoptosis 36 of several types of cancer cells (9-13), and sensitizes tumor cells to cytotoxic agents or radiation 37 (14, 15) . Because of this, BMI1 is an attractive target for future clinical therapies of different cancers.
38
BMI1 overexpression is a well-established inducer of cancer cell proliferation and resistance to cancer 39 drug treatments of various cancer cell lines (16) (17) (18) , highlighting the potential of specific BMI1 40 inhibitors. However, although BMI1 inhibition results in growth reduction and cell death of different 41 cancer cell lines, the underlying mechanisms are often context-dependent and uncertain (11, 13, 19) . As 42 a result, little is known about the genetic interactions and variations involved in BMI1 inhibition-43 derived lethality or the subsequent resistance.
44
In the present study, we performed a genome-wide screen for gene disruptions that could result in 45 resistance to pharmacological inhibition of BMI1 by exposing mutagenized human haploid HAP1 cells 46 to low concentrations of the BMI1-inhibitor AB057609107 (PTC-318). PTC-318 is a new inhibitor of BMI1, developed by PTC Therapeutics, USA, that is designed to regulate BMI1 expression post-48 transcriptionally. We show that reduction of BMI1 levels by short hairpin RNA (shRNA) or inhibition 49 with the small molecule inhibitor PTC-318 significantly reduced cell viability of different cancer cell 50 lines. Through our genetic screen, we unveiled new genes that rescue cell death induced by BMI1 51 inhibitors and selected NUMA1 for follow-up studies. We identified a novel mitotic mechanism 52 underlying BMI1-associated lethality using CRISPR-Cas9 derived knockouts of NUMA1 in both HAP1 cells and non-small lung cancer (NSLC) cell lines. Our results highlight a mechanism relying on mitotic 54 arrest upon loss of BMI1 and a new genetic resistance mechanism. These observations add further 55 knowledge to the complex and context-dependent involvement of BMI1 in cancer. Our findings 56 contribute to a better understanding of BMI1-associated pharmacological cancer treatment strategies.
58
Results
59
Loss of BMI1 induces cell death in cancer cell lines 60 In order to test BMI1-dependent lethality in HAP1 cells, we transduced doxycycline-responsive plasmid 61 systems into wild-type HAP1 cells to generate an inducible expression of shRNA targeting BMI1 62 (shBMI1) or control shRNA (shRND). We assessed knockdown efficiency upon doxycycline treatment 63 by comparing RNA and protein levels at different time points. As expected, doxycycline-induced 64 shBMI1 resulted in a decreased BMI1 expression, both at RNA (avg knockdown, 93%) and protein 65 level after 48 hours of doxycycline treatment (Fig 1A and 1B) .We next evaluated HAP1 cell viability 
91
To avoid inhibitor-derived side-effects, we screened for the lowest concentrations of PTC-318, leading 92 to cell death. PTC-318 titrations showed that treatment with low nanomolar concentrations (>20 nM) 93 resulted in reduced BMI1 protein expression compared with dimethyl sulfoxide (DMSO) treated HAP1 94 control ( Fig 1E) . Moreover, 20nM and 40nM PTC-318 treatment-induced cell death as measured by 95 colony formation and cell proliferation assays (Fig 1F, 1G, and S1 Fig) . These results suggest that 96 similar to BMI1 knockdown, the pharmacological inhibition of BMI1 with nanomolar concentrations 97 of PTC-318 induces lethality in HAP1 cells.
98
In order to confirm that PTC-318-induced lethality was caused by BMI1 regulation and to exclude 99 potential off-target toxicity, we expressed BMI without its UTR in HAP1 cells. These cells showed 100 increased BMI1 protein levels compared with wild-type HAP1 cells. Importantly, upon treatment with 101 PTC-318, cells ectopically expressing BMI1 showed increased resilience to PTC-318 treatment compared with wild-type HAP1 cells (Fig 2A and 2B ), suggesting that BMI1 transcriptional inhibition 103 is responsible for PTC-318 cytotoxicity. In essence, wild-type HAP1 cells were transduced with a retroviral GFP gene trap that randomly 127 integrates into the genome. The gene trap most commonly integrates into introns and can land in two 128 orientations: sense or antisense. Owing to the unidirectional design of the gene trap sense-orientation 129 integrations are likely to produce truncated and impaired transcription products. (Fig 2C) .
130
We subjected mutagenized HAP1 cells to a stringent selection with 40 nM of PTC-318 for two weeks.
131
Next, the genomic DNA of surviving HAP1 cells was isolated, and the insertion sites were subsequently 132 amplified and sequenced. Gene trap integrations were then assigned to genes and counted as 133 inactivating integrations if inserted in sense with the transcriptional orientation in an intron or regardless 134 of orientation in an exon. To identify genes enriched in the PTC-318 treated population, we compared 135 the number of disruptive integrations per gene in our experimental dataset with a non-treated control 136 dataset using a one-sided Fisher's exact test. We applied a stringent cut-off and considered all genes 137 with an FDR-corrected p-value lower than 10 -5 as enriched for inactivating integrations.
138
Interestingly, we found several reported antagonists of Polycomb repressors among the most significant 139 hits required for cell survival, including two genes (PBRM1 and ARID2) encoding essential PBAF 140 subgroup proteins of the nucleosome remodeling complex SWI-SNF, (Fig 2D and S1 Table) .
141
Strikingly, the most significantly enriched gene in the HAP1 population, NUMA1 (p<0.0001) had not 142 previously been associated with BMI1. NUMA1 encodes a 238 kDa nuclear mitotic apparatus protein,
143
which is mainly reported to be involved in dynein-associated tethering of spindle pole microtubules 144 during mitosis, recruiting dynein to the cell cortex (26-28). NUMA1 has also been implicated in a 145 conserved mechanism establishing asymmetric cell division associated with differentiation. The `
146
features associated with NUMA1, as well as its tumor suppressive and cell differentiating properties
147
(29-32), suggested it as an attractive BMI1-antagonizing candidate, especially considering the role of 148 BMI1 in maintaining cell stemness in healthy and cancer cells. To understand this new genetic 149 association, we decided to focus on NUMA1-loss as a possible resistance-inducing mechanism against 150 BMI1 inhibition.
Knockout of NUMA1 in HAP1 cells induces resistance to cell death
152 upon BMI1 inhibition 153 As validation of the screen results, we checked whether loss of NUMA1 expression would result in 154 resistance to the lethality induced by BMI1 inhibition. We generated clonal NUMA1 knockout HAP1 155 cell lines (NUMA1-KO) by targeting the first exon of NUMA1 with CRISPR-Cas9. (Fig 3A and 3D) .
156
We found that NUMA1-KO cells were significantly more resistant to the toxicity of shRNA knockdown 157 of BMI1 or PTC-318 treatment compared with wildtype HAP1 (hereafter named NUMA1-WT) cells 158 ( Fig 3B and 3E) . We found a more than 2-fold higher cell viability in NUMA1-KO cells compared to
159
WT upon BMI1 knockdown and inhibition, respectively, following quantification of Alamar blue-160 stained cells ( Fig 3C and 3F) . 
176
In order to further validate that the NUMA1-KO resistance was specific to BMI1 inhibition, we 177 attempted to establish BMI1 knockout (BMI1-KO) HAP1 clones. We transfected NUMA1-WT or 178 NUMA1-KO HAP1 cells with CRISPR-Cas9 targeting BMI1, hypothesizing that NUMA1-WT cells 179 would survive the BMI1-KO to a lesser extent compared with NUMA1-KO cells. While we were able 180 to establish ten BMI1-KO clones in NUMA1-KO background, we retrieved only one NUMA1-WT 181 clone with reduced BMI1 expression ( Fig 3G and 3H) .
182
These results indicated that loss of NUMA1 results in resistance to the toxicity resulting from loss of 183 BMI1, whether induced by shRNA, inhibitor, or CRISPR-Cas9. It also further confirmed the BMI1-184 specific effect of PTC-318 and that the NUMA1-derived resistance is specific to BMI1-associated 185 lethality.
186

BMI1-loss induces mitotic arrest and cell death 187
Since NUMA1 is important for proper mitotic progression, we assessed the cell cycle profiles of HAP1
188 cells treated with a lower concentration of PTC-318 (20nM). We chose the lower concentration in order 189 to maintain target engagement and limit loss of cell viability.
190
Both genetic knockdown and pharmacological inhibition of BMI1 resulted in increased numbers of 191 cells arrested in mitosis, as shown by the increase in Histone H3 phosphorylation (pH3). Compared 192 with shRND or DMSO controls, BMI1 knockdown and PTC-318 treatment resulted in a 2-fold and 8-
193
fold increase in pH3 positive cell populations, respectively ( Fig 4A) . Having confirmed mitotic arrest induced by BMI1 inhibition, we next followed the mitotic progression 213 of HAP1 by live-cell imaging upon doxycycline treatment at different time-points (24, 48, and 72 hours) 214 or 20 nM PTC-318 treatment. We found a modest albeit significantly increased time spent in mitosis in 215 all doxycycline-induced shBMI1 HAP1 cells (41, 45, and 53 minutes, respectively) compared with 216 control cells (34 minutes) ( Fig 4B and S2 Fig) .
217
In contrast to the modest increases of time spent in mitosis observed in shBMI1 cells, analysis of 218 NUMA1-WT HAP1 cells treated with PTC-318 showed a more prolonged mitotic arrest compared with 219 DMSO-treated cells. While the mitotic duration of DMSO-treated cells was 31 minutes, PTC-318 220 treated NUMA1-WT cells spent 131 minutes in mitosis. In general, we observed that BMI1 inhibition 221 with PTC-318 resulted in a robust mitotic arrest in both NUMA1-WT and NUMA1-KO cell lines.
222
However, the arrest was longer in NUMA1-WT than in NUMA1-KO cell lines (131 minutes and 92 223 minutes, respectively).
After observing mitotic arrest induced by BMI1 inhibition, through both shBMI1 and PTC-318, we 225 examined the fate of these cells by live-cell imaging (Fig 4C) . While most of the untreated cells 226 underwent chromosome segregation and completed cell division, we observed an enrichment of mitotic 227 cell death upon BMI1 inhibition. This effect was more pronounced in PTC-318-treated cells than in the 228 shBMI1 population.
229
It has been described that the balance between two competing networks dictates cell fate. While the 230 CyclinB1/cyclin-dependent kinase 1 (CDK1) complex is essential for mitotic progression, opposing 231 signals, regulating, for example, the apoptosis-regulating protein B-cell lymphoma 2 (BCL-2), can 232 induce mitotic cell death. The fate of a cell in mitotic arrest is thus linked to the antagonizing levels and 233 timing of these two independent networks: if cell death signals increase, CyclinB1 levels decrease (33).
234
Thus, we measured the expression levels of CyclinB1/CDK1 and BCL-2 in BMI1-inhibited HAP1 cells.
235
Consistent with the observed mitotic arrest, both CDK1 and CyclinB1 protein levels were elevated at 236 early time-points after PTC-318 treatment (between 2 and 4 hours), and remained high up to 24 hours 237 after treatment (Fig 4D) . In agreement with these results, live-cell imaging data showed that the onset 238 of mitotic arrest was around 3-4 hours after treatment (S3 Fig). In order to quantify cell death signals 239 induced by BMI1 inhibition, we determined RNA levels of the anti-apoptotic marker BCL-2 and 240 observed a significant decrease after PTC-318 treatment compared with DMSO-treated control cells 241 ( Fig 4E) . Similar to PTC-318 treatment, induction of shBMI1 in the HAP1 cells significantly decreased 242 BCL2 expression. Together, these results suggest that BMI1 inhibition induces mitotic arrest in HAP1 243 cells, ultimately causing cell death in the NUMA1-WT background but not in the NUMA1-KO 244 population.
245
Inhibition of BMI1 induces cell death in NSCLC cell lines in mitosis 246
We asked whether toxicity associated with BMI1-inhibition was could be relevant in other cancer cell 247 types and rule out that our findings were limited to haploid cells. Previous studies have demonstrated 248 that BMI1 is overexpressed in non-small cell lung cancer (NSCLC) and that its expression was 249 associated with NSCLC progression (34) (35) (36) . We, therefore, tested whether NSCLC would be sensitive to BMI1 inhibition. We treated NSCLC cell lines h520 and SK-MES-1 with PTC-318 and found that,
251
as in HAP1 cells, low nanomolar concentrations of PTC-318 resulted in a significant reduction in cell 252 survival of both lines (IC50 h520: 1.9 nM) (IC50 SK-MES-1: 7.8 nM) compared with untreated 253 controls. (Fig 5A and 5B) . Both NSCLC cell lines showed a significant accumulation pH3 mitotic 254 marker upon PTC-318 treatment, further suggesting that our findings in the HAP1 population can be 255 generalized to other cancer types (Fig 5C and 5D) . Finally, we validated the essential function of BMI1 in NSCLC as we did for HAP1 cells. We 272 transfected the two NSCLC cell lines with CRISPR-Cas9 targeting BMI1 and sorted single-cell clones.
273
While we were not able to grow any single clones from the transfected SK-MES-1 population, we 274 retrieved six h520 clones after single-cell sorting. Five of these clones showed regular expression of BMI1, and one showed reduced BMI1 expression ( Fig 5F) . Interestingly, the clone with the lowest 276 BMI1 expression also showed reduced levels of NUMA1 compared with the other h520 cell clones.
277
These observations are in line with our main finding that BMI1 inhibition is tolerated only in the context 278 of NUMA1 knockout or at least NUMA1 reduction, while it is lethal in NUMA1-proficient cells.
279
Altogether, we were able to show mitotic arrest and cytotoxicity caused by BMI1 loss in two commonly 280 used NSCLC in vitro models, indicating that the observed phenotypes related to BMI1 inhibition extend 281 to non-haploid cancer cells as well.
282
Discussion
283
Loss of BMI1 has been shown to induce growth arrest and cell death in cancer cells both in vitro and in 284 vivo (37-39). However, although BMI1 inhibition leads to impaired cell proliferation in different 
331
In light of our screening results and the reported role of NUMA1 in the cell cycle, we further validated 332 that inhibition of BMI1 in NUMA1 proficient cells resulted in a mitotic arrest followed by cell death in 333 mitosis, a phenotype that could be rescued by inactivation of NUMA1. The mitotic arrest observed in 334 our study upon inhibition of BMI1 coincided with increases in CDK1 and Cyclin-B1 protein levels.
335
The findings further support previous studies demonstrating a CDK1-induced switch from mitotic arrest 
344
In conclusion, our results investigating the effects of PTC-318 on cancer cell lines indicate that 345 inhibition of the oncogene BMI1 induces cancer cell death, making it a potential approach to treat 346 certain types of cancers -either as a single agent or in combination with other inhibitors. The emergence 347 and testing of new BMI1 inhibitors for the treatment of cancer suggest that BMI1 is a relevant target 348 for cancer therapy. In our study, we unveiled how the inhibition of BMI1 induces cell death through 349 mitotic arrest that was successfully rescued by the depletion of NUMA1 expression. In our experimental 350 set-up, NUMA1-mutations strongly associated with cancer cell survival and may have an essential role
351
-and hence serve as a potential biomarker -in resistance mechanisms in treatments associated with 352 BMI1 inhibition. Although further studies are needed to establish a complete picture of the pathways 353 and mechanisms linked with BMI1 overexpression and inhibition in cancer, our findings highlight an essential and novel mechanism of BMI1 in cancer cells, which could contribute to the development of 355 effective cancer therapies.
356
Materials and Methods
357
Cell culture 358 HAP1 cells have been described previously (49). They and were maintained in IMDM + GlutaMAX
359
(Gibco) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich), and penicillin-streptomycin 360 (Gibco). NSCLC cell lines h520 and SK-MES-1 (provided by the A. Berns laboratory at the 361 Netherlands Cancer Institute, Amsterdam, the Netherlands) were maintained in DMEM/F12 + 362 GlutaMAX (Gibco) supplemented with 10% FCS and penicillin-streptomycin (Gibco).
363
Haploid genetic screen
364
Procedures for the generation of gene-trap retrovirus and HAP1 mutagenesis have been described 365 previously (22, 49) . To select HAP1 variants resistant to BMI1 inhibitor PTC-318, approximatively 366 10 8 mutagenized HAP1 cells (>90% haploid) were seeded in fourteen T175 cell culture flasks. The 367 cells were exposed to 40 nM of PTC-318 24 hours after seeding and incubated for fourteen days.
368
Surviving HAP1 clones were trypsinized and washed before amplification and analysis of integration 369 sites, as described in (22, 50) . In brief, as a first step insertion sites were amplified in a linear 370 amplification reaction using a biotinylated primer. Products were captured on streptavidin-coated 371 magnetic beads, washed, and subjected to single-stranded DNA linker ligation followed by a second 
Cell viability assay 435
To assess cell viability upon PTC-318 treatment, 40,000 HAP1 cells/well or 20,000 HAP1 cells/well 436 were plated in 24-well plates (500 μl/well) and incubated for 24 hours at 37°C. Next, the cells were 437 treated with respective concentrations of PTC-318 (as described above) and incubated for 48 hours.
438
Alamar blue (10X; Invitrogen) was diluted 1:10 in corresponding cell medium and distributed to cells.
439
Negative control cells received 3 μl of 20% sodium dodecyl sulfate (SDS). Cell viability was 440 determined by measuring the relative fluorescence 4-6 hours after addition of alamar blue using the 441 HP D300 Digital Dispenser.
442
To assess viability upon BMI1-KD, 2,000 cells were plated in 24-well plates with or without 443 doxycycline (500 μl/well) and incubated for 24 hours at 37°C. The doxycycline was refreshed every 444 day for one week before adding the alamar blue as previously described.
445
Flow cytometry analysis 446
For PTC-318, 200,000 cells were plated, treated with PTC-318, and incubated for 48 hours before 447 collection. For shBMI1, 100,000 cells were plated and incubated for 96 hours. Doxycycline was 448 refreshed every day. After corresponding incubation times, equal amounts of cells (500,000-449 2,000,000) were collected after trypsinization, and thereafter centrifuged, fixed with 70% ethanol, and 450 stored at -20°C until staining. For staining, cells were centrifuged for 3 minutes at 1,500 rpm and then 451 washed in PBS. Cells were centrifuged again at 1,500 for 3 minutes and pellets were resuspended in 452 0.25% Triton X-100 (Sigma), transferred to 1.5 ml tubes, and incubated on ice for 15 minutes for permeabilization. Cells were centrifuged at 5,000 g for three minutes, resuspended in PBS containing 454 1% BSA and 1:100 mouse anti phospho-Histone H3 (Cell signaling, 9701), and incubated for 1 hour 455 at room temperature. After washing, cells were resuspended in PBS containing 1% BSA and 1:300
456
Alexa 647 conjugated donkey anti-mouse (Thermofisher, A21238) and incubated for 30 min at room 457 temperature and in the dark. Cells were thereafter washed, resuspended in 150 ul PBS containing 10 458 ug/ml DNase-free RNase A, and incubated for 30 min at 37°C. Prepared cells were stored in -20°C or 459 4°C until analysis on flow cytometer (LSR II). Propidium iodide (1.5 ug) was added to the samples 460 right before assessment.
461
Live cell imaging 462 Cells were plated on LabTek dishes and two hours before imaging, the media was changed to 463 Leibovitz L15 CO2-independent cell culture medium (Gibco). Mitotic progression was followed by 464 adding SiR-DNA (Spirochrome) and drugs to the cells, that were imaged as previously described (53).
465
In the case of shRNA-mediated knockdown of BMI1 (shBMI1), doxycycline was added to the cells 466 24, 48, or 72 hours prior to SiR-DNA addition. Cells were imaged every 15 minutes in a heated 467 chamber of 37 °C using a 20x NA 0.95 air objective on an IX71 microscope (Olympus), controlled by 468 SoftWoRx 6.0 software (Applied Precision). 
469
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